Search results
Results from the WOW.Com Content Network
Dydrogesterone, sold under the brand name Duphaston among others, [1] is a progestin medication which is used for a variety of indications, including threatened or recurrent miscarriage during pregnancy, dysfunctional bleeding, infertility due to luteal insufficiency, dysmenorrhea, endometriosis, secondary amenorrhea, irregular cycles, premenstrual syndrome, and as a component of menopausal ...
Premenstrual dysphoric disorder; Other names: Late luteal phase dysphoric disorder: Specialty: Psychiatry: Symptoms: Severe mood swings, depression, irritability, agitation, uneasiness, change in appetite, severe fatigue, anxiety, anger insomnia/hypersomnia, breast tenderness, decreased interest in usual social activities, reduced interest in sexual activity, difficulty in concentration
Premenstrual syndrome (PMS) is a disruptive set of emotional and physical symptoms that regularly occur in the one to two weeks before the start of each menstrual period. [ 4 ] [ 5 ] Symptoms resolve around the time menstrual bleeding begins. [ 4 ]
Due to the unclear etiology of premenstrual syndrome and premenstrual dysphoric disorder, symptom relief is the primary goal of treatment. Selective serotonin reuptake inhibitors and spironolactone decrease physical and psychological symptoms associated with premenstrual syndrome.
Progesterone (P4), sold under the brand name Prometrium among others, is a medication and naturally occurring steroid hormone. [20] It is a progestogen and is used in combination with estrogens mainly in hormone therapy for menopausal symptoms and low sex hormone levels in women.
This cluster of symptoms is often referred to as premenstrual syndrome (PMS). For some individuals, the psychopathological symptoms associated with menstruation can be severe and debilitating, leading to a condition known as premenstrual dysphoric disorder (PMDD). PMDD is characterized by intense mood disturbances, cognitive, and somatic ...
[3] [4] The guidelines have been widely used across the UK and helped reduce variations by standardising approach to inpatient diabetes care. [1] Hypoglycaemia [5] Diabetic Ketoacidosis (DKA) in Adults [6] Hyperosmolar hyperglycemia state (HHS) in adults with diabetes [7] Glycaemic control in people with cancer [8] Diabetes at the front door [9]
Jansen's metaphyseal chondrodysplasia (JMC) is a disease that results from ligand-independent activation of the type 1 of the parathyroid hormone receptor, due to one of three reported mutations (activating mutation).